drugset / Trial / NCT05867030
Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma
RandomizedParallel-groupSingle-blindTreatment
Summary
A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
Timeline
- Start
- 2023-07-28
- Primary completion
- 2029-08-31
- Completion
- 2033-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 20 mg | Oral |
| Subject | Parsaclisib | Small molecule | 2.5 mg | Oral |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |